Healthy Male Subjects Clinical Trial
Official title:
A Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
Verified date | January 2020 |
Source | JHL Biotech, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) Sourced from the European Union (EU) and the Union States (US) in Healthy Male Volunteers
Status | Completed |
Enrollment | 154 |
Est. completion date | December 13, 2019 |
Est. primary completion date | September 17, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 21 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male volunteers, 2. Age range of 21-55 years (inclusive). 3. BMI range of 18.0-30.0 kg/m2 (inclusive) and a total body weight >50 kg. 4. Medically healthy subjects with normal organ functions and laboratory values 5. Subjects must be willing to use adequate contraception and not donate sperm from admission to clinical research center until 6 months post dosing. 6. All intermittent medications including over the counter, herbal and nutriceuticals, must be stopped at least 14 days prior to admission to the clinical research center. 7. Ability and willingness to abstain from alcohol 48hrs prior to admission to the clinical research center, and throughout the dosing and evaluation period. 8. No significant medical history per the PI judgment. 9. ECGs (via 12 lead) showing normalized cumulative sum (NCS) findings per PI judgment 10. Ability to provide informed consent for the study. Exclusion Criteria: 1. Previous treatment with an anti-vascular endothelial growth factor (VEGF) antibody or any other antibody or protein targeting the VEGF receptor or treatment with an immunobiological drug during the last three months. 2. Previous history of cancer other than adequately treated basal cell or squamous cell carcinoma of the skin. 3. Received blood transfusions and blood donation within 3 months before screening date. 4. Resting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg. 5. Any other severe physical incapacity. 6. Positive serological test for hepatitis B surface antigen or positive antibody for hepatitis C virus or positive antibody for human immunodeficiency virus (type 1 and 2). 7. Tuberculosis (TB) or an acute systemic infection; demonstrated by positive QuantiFERON-TB and/or Chest radiograph conducted up to 3 months prior or during the screening visit. 8. Major surgery planned for the study duration or cases with major surgery in the past 28 days before screening. 9. History of relevant drug and/or food related allergies. 10. History of or known hypersensitivity to bevacizumab or other recombinant human or humanized antibodies or inactive ingredients. 11. History of alcohol and or drug abuse/addiction. 12. Positive alcohol breath test and drug screen for opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines. 13. Strenuous exercise 96 hrs prior to admission to the clinical research center. 14. Any significant or acute illness within 30 days prior to the expected first dose of study drug. 15. Unsuitable veins for infusion and/or venepuncture. 16. History of bleeding disorders, thromboembolic conditions, gastrointestinal perforations or any fistulae, orthostatic hypotension, fainting spells, blackouts for any reasons; as well as presence of a non-healing wound or fracture. 17. Participation in another clinical study where the investigational drug was received within < 5 x half-lives of the drug (120 days prior to screening). 18. Any condition or displayed behaviour that the investigator in their best clinical judgement believes could be detrimental the subject's participation in the study or result in unfavourable outcomes for the subject or study (eg. Clear signs that the patient is withholding information on their substance use/abuse status). |
Country | Name | City | State |
---|---|---|---|
Bulgaria | MHAT Lyulin EAD | Sofia |
Lead Sponsor | Collaborator |
---|---|
JHL Biotech, Inc. |
Bulgaria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC0-inf | area under the concentration-time curve from time zero to infinity (AUC0-inf) | up to 71 days | |
Secondary | AUClast | Area under the serum concentration-time curve from time 0 to last quantifiable concentration (AUClast). | up to 71 days | |
Secondary | Cmax | Maximum serum concentration just prior to end of infusion (Cmax) | up to 71 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05621447 -
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
|
Phase 1 | |
Completed |
NCT02901366 -
Mass Balance Study of FYU-981
|
Phase 2 | |
Not yet recruiting |
NCT01928563 -
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine
|
Phase 1 | |
Completed |
NCT05559554 -
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
|
Phase 1 | |
Completed |
NCT04512872 -
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT06111196 -
Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03317652 -
Effect of Sodium Nitroprusside on Cerebral Blood Flow
|
N/A | |
Completed |
NCT04655872 -
Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02609711 -
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
|
Phase 1 | |
Withdrawn |
NCT02560363 -
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT01261260 -
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05072028 -
Mass Balance and Biotransformation Study of [14C]DBPR108 in Human
|
Phase 1 | |
Completed |
NCT05446233 -
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05275010 -
A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System
|
Phase 1 | |
Completed |
NCT04839744 -
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05792917 -
Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT04825431 -
Mass Balance Study of [14C] TAS-205 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01819779 -
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
|
Phase 1 | |
Completed |
NCT05126784 -
AVT03 With Prolia in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT04850638 -
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
|
Phase 1 |